Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of HYQVIA in CIDP (ADVANCE-CIDP 3)
NCT02955355Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2016
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Takeda. Primary endpoints: Number of Participants With Any Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), Regardless of Causality up to 6.6 years, Number of Participants With Causally Related Treatment-emergent SAEs and AEs up to 6.6 years and 6 more. Started Nov 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02955355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955355.